

# **EXHIBIT 14**

Patricia G. Moorman, Ph.D.

1 IN THE UNITED STATES DISTRICT COURT  
2 FOR THE DISTRICT OF NEW JERSEY

3

4

5 IN RE: JOHNSON & JOHNSON )  
6 TALCUM POWER PRODUCTS MARKETING, ) MDL NO.  
7 SALES PRACTICES, AND PRODUCTS ) 16-2738 (MAS) (RLS)  
8 LIABILITY LITIGATION )

9

10

11

DEPOSITION

12

OF

13

PATRICIA G. MOORMAN, Ph.D.

14

15

Tuesday, February 13, 2024

16

17

18

19

GOLKOW LITIGATION SERVICES, INC.  
877.370.3377 ph | 917.591.5672 fax  
20 deps@golkow.com

21

22

23

24

25

1 Q. So that means 11 out of 24  
2 case-control studies did not show a significant  
3 association, right?

4 A. Not a statistically significant  
5 increased risk, yes. Although, it is important to  
6 look at the point estimates overall, which are --  
7 nearly all of them report point estimates greater  
8 than 1.

9 Q. So you consider those studies to be  
10 consistent despite the fact that 11 did not show a  
11 statistically significant association?

12 MS. PARFITT: Objection. Form.

13 THE WITNESS: As I stated earlier, I  
14 do not use statistical significance as a  
15 way to dichotomize, yes, there is an  
16 association; no, there is not.

17 Look at the point estimate, and from  
18 the standpoint that the vast majority of  
19 studies show reported point estimates  
20 greater than 1 with a majority of them  
21 being statistically significant, I would  
22 say, yes, the findings are quite  
23 consistent.

24 BY MS. DAVIDSON:

25 Q. If you look at Table 2 of Taher. For